###begin article-title 0
Repeat-induced epigenetic changes in intron 1 of the frataxin gene and its consequences in Friedreich ataxia
###end article-title 0
###begin p 1
The authors wish it to be known that, in their opinion, the first four authors should be regarded as joint First Authors.
###end p 1
###begin p 2
Present address: Eriko Greene, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
###end p 2
###begin p 3
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 3
###begin p 4
###xml 101 104 101 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 223 226 223 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 1265 1268 1265 1268 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 414 422 <span type="species:ncbi:9606">patients</span>
###xml 1282 1290 <span type="species:ncbi:9606">patients</span>
Friedreich ataxia (FRDA), the most common hereditary ataxia, is caused by mutations in the frataxin (FXN) gene. The vast majority of FRDA mutations involve expansion of a GAA*TTC-repeat tract in intron 1, which leads to an FXN mRNA deficit. Bisulfite mapping demonstrates that the region adjacent to the repeat was methylated in both unaffected and affected individuals. However, methylation was more extensive in patients. Additionally, three residues were almost completely methylation-free in unaffected individuals but almost always methylated in those with FRDA. One of these residues is located within an E-box whose deletion caused a significant drop in promoter activity in reporter assays. Elevated levels of histone H3 dimethylated on lysine 9 were seen in FRDA cells consistent with a more repressive chromatin organization. Such chromatin is known to reduce transcription elongation. This may be one way in which the expanded repeats contribute to the frataxin deficit in FRDA. Our data also suggest that repeat-mediated chromatin changes may also affect transcription initiation by blocking binding of factors that increase frataxin promoter activity. Our results also raise the possibility that the repeat-mediated increases in DNA methylation in the FXN gene in FRDA patients are secondary to the chromatin changes.
###end p 4
###begin title 5
INTRODUCTION
###end title 5
###begin p 6
###xml 62 63 62 63 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 439 442 439 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 486 489 486 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 633 634 633 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 680 683 680 683 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 723 724 723 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 725 726 725 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 849 850 849 850 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 143 151 <span type="species:ncbi:9606">patients</span>
Friedreich ataxia (FRDA) is the most common inherited ataxia (1). The ataxia, which is recessively inherited, is relentlessly progressive with patients frequently becoming wheelchair-bound in their early teens. Hypertrophic cardiomyopathy is a common co-morbid feature of FRDA, with congestive heart failure being a frequent cause of death. The most common cause of FRDA is the expansion of a GAA*TTC-repeat (henceforth referred to as the FXN repeats) in intron 1 of the frataxin gene (FXN). Unaffected individuals have at least one allele with 8-33 repeats, while most individuals with FRDA have 90 or more repeats in both alleles (1). These expanded alleles produce less mature FXN mRNA than alleles in the normal range (2,3). This results in a deficiency of frataxin, an essential protein thought to be involved in mitochondrial iron metabolism (1).
###end p 6
###begin p 7
###xml 4 7 4 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 58 66 58 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 68 69 68 69 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 70 71 70 71 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 117 120 117 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 148 151 148 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 342 343 342 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 478 479 478 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 636 637 636 637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 735 738 735 738 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 1010 1011 1010 1011 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 1112 1117 1112 1117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10 B11 B12 B13">10&#8211;13</xref>
###xml 1152 1155 1152 1155 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 1285 1288 1285 1288 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 1517 1520 1517 1520 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 268 273 <span type="species:ncbi:9606">human</span>
###xml 622 627 <span type="species:ncbi:10090">mouse</span>
The FXN repeats form an intrinsic block to RNA polymerase in vitro (4,5), suggesting one potential mechanism for the FXN mRNA deficit. However, the FXN repeats may affect transcription in other ways. For example, the long stretches of tandem repeats present in normal human centromeres are associated with transcriptionally silent chromatin (6) as are the genes containing the expanded triplet repeat tracts responsible for Fragile X syndrome and congenital myotonic dystrophy (7). In addition, transgenes containing long GAA*TTC-tracts become associated with heterochromatin when inserted into arbitrary locations in the mouse genome (8). It is thus possible that repeat-mediated chromatin changes also contribute to the reduction in FXN transcript in FRDA. In principle, changes in chromatin modifications in non-coding sequence could affect transcription by affecting RNA polymerase II elongation or by changing the accessibility of this region to regulatory factors important for transcription initiation (9). Since the first intron of many genes contains regulatory sequences important for gene expression (10-13) and the sequence adjacent to the FXN repeat is the region of intron 1 most likely to be affected by repeat expansion, we examined the contributions of this region to FXN promoter activity. We also examined the chromatin modifications and DNA methylation status of this region in cells from unaffected individuals and individuals with FRDA. We have identified a region that is important for maximal FXN gene expression and shown that repeat expansion leads to changes in DNA methylation and chromatin organization in this region. Our data also suggests how these changes may lead to the frataxin deficit responsible for FRDA.
###end p 7
###begin title 8
MATERIALS AND METHODS
###end title 8
###begin title 9
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In silico</italic>
In silico analysis of intron 1
###end title 9
###begin p 10
###xml 66 69 66 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 143 145 143 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 276 278 276 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
Primate sequences in the region of intron 1 immediately 5' of the FXN repeat were aligned using the online version of the Multalin algorithm [(14); ]. The repeated DNA elements in this region were identified using the Repeat Masker track generated using the RepBase database (15). This region was also analyzed for potential transcription factor binding sites using MatInspector and Matrix Family Library Version 4.1 ().
###end p 10
###begin title 11
Cell lines and DNA
###end title 11
###begin p 12
###xml 452 455 452 455 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 531 532 531 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 533 535 533 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 917 924 917 924 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 926 934 926 934 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 1.</label>
###xml 934 976 934 976 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="13">Oligonucleotides used in these experiments</p>
###xml 934 976 934 976 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="13">Oligonucleotides used in these experiments</p></caption>
###xml 976 983 976 983 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Primers</bold>
###xml 976 983 976 983 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"><bold>Primers</bold></td>
###xml 983 983 983 983 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"/>
###xml 976 983 976 983 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1"><bold>Primers</bold></td><td rowspan="1" colspan="1"/></tr>
###xml 983 986 983 986 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 983 992 983 992 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"><italic>FXN</italic>Me74-F</td>
###xml 992 1051 992 1051 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">5&#8242;-TTTTTCTCGAGAATAAGGTATAGAGAGGTTAATTAATTTGTTTTTTGGTTATA-3&#8242;</td>
###xml 983 1051 983 1051 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1"><italic>FXN</italic>Me74-F</td><td rowspan="1" colspan="1">5&#8242;-TTTTTCTCGAGAATAAGGTATAGAGAGGTTAATTAATTTGTTTTTTGGTTATA-3&#8242;</td></tr>
###xml 1051 1054 1051 1054 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 1051 1061 1051 1061 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"><italic>FXN</italic>Me956-R</td>
###xml 1061 1103 1061 1103 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">5&#8242;-TTTTTGAATTCCCCTCCACCAACCTACCCTACCTTC-3&#8242;</td>
###xml 1051 1103 1051 1103 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1"><italic>FXN</italic>Me956-R</td><td rowspan="1" colspan="1">5&#8242;-TTTTTGAATTCCCCTCCACCAACCTACCCTACCTTC-3&#8242;</td></tr>
###xml 1103 1106 1103 1106 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 1103 1114 1103 1114 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"><italic>FXN</italic>Me1212-F</td>
###xml 1114 1172 1114 1172 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">5&#8242;-TTTTTCTCGAGGAGGTGAAATTTTTAGAGTTGTAGAATAGTTAGAGTAGTAG-3&#8242;</td>
###xml 1103 1172 1103 1172 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1"><italic>FXN</italic>Me1212-F</td><td rowspan="1" colspan="1">5&#8242;-TTTTTCTCGAGGAGGTGAAATTTTTAGAGTTGTAGAATAGTTAGAGTAGTAG-3&#8242;</td></tr>
###xml 1172 1175 1172 1175 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 1172 1183 1172 1183 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"><italic>FXN</italic>Me1930-R</td>
###xml 1183 1235 1183 1235 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">5&#8242;-TTTTTGAATTCACCTCCCAAAATACTAAAATTATAAACATAAACCA-3&#8242;</td>
###xml 1172 1235 1172 1235 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1"><italic>FXN</italic>Me1930-R</td><td rowspan="1" colspan="1">5&#8242;-TTTTTGAATTCACCTCCCAAAATACTAAAATTATAAACATAAACCA-3&#8242;</td></tr>
###xml 1235 1238 1235 1238 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 1235 1241 1235 1241 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"><italic>FXN</italic>PrF</td>
###xml 1241 1298 1241 1298 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">5&#8242;-TTTTTTACGCGTGCTATGATGGCCGGGCTGGAATGCTGTGGCTATTCACAG-3&#8242;</td>
###xml 1235 1298 1235 1298 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1"><italic>FXN</italic>PrF</td><td rowspan="1" colspan="1">5&#8242;-TTTTTTACGCGTGCTATGATGGCCGGGCTGGAATGCTGTGGCTATTCACAG-3&#8242;</td></tr>
###xml 1298 1301 1298 1301 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 1298 1308 1298 1308 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"><italic>FXN</italic>-Luc-F1</td>
###xml 1308 1333 1308 1333 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">5&#8242;-ACCGACATCGATGCGACCT-3&#8242;</td>
###xml 1298 1333 1298 1333 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1"><italic>FXN</italic>-Luc-F1</td><td rowspan="1" colspan="1">5&#8242;-ACCGACATCGATGCGACCT-3&#8242;</td></tr>
###xml 1333 1336 1333 1336 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 1333 1343 1333 1343 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"><italic>FXN</italic>-Luc-R2</td>
###xml 1343 1372 1343 1372 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">5&#8242;-TTGCTCTCCAGCGGTTCCATCTT-3&#8242;</td>
###xml 1333 1372 1333 1372 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1"><italic>FXN</italic>-Luc-R2</td><td rowspan="1" colspan="1">5&#8242;-TTGCTCTCCAGCGGTTCCATCTT-3&#8242;</td></tr>
###xml 1372 1375 1372 1375 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 1372 1383 1372 1383 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"><italic>FXN</italic>chip-QF1</td>
###xml 1383 1409 1383 1409 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">5&#8242;-GCAAAGGCCAGGAAGGCGGA-3&#8242;</td>
###xml 1372 1409 1372 1409 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1"><italic>FXN</italic>chip-QF1</td><td rowspan="1" colspan="1">5&#8242;-GCAAAGGCCAGGAAGGCGGA-3&#8242;</td></tr>
###xml 1409 1412 1409 1412 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 1409 1420 1409 1420 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"><italic>FXN</italic>chip-QR1</td>
###xml 1420 1446 1420 1446 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">5&#8242;-ATGGCTTGGACGTGGCCTGC-3&#8242;</td>
###xml 1409 1446 1409 1446 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1"><italic>FXN</italic>chip-QR1</td><td rowspan="1" colspan="1">5&#8242;-ATGGCTTGGACGTGGCCTGC-3&#8242;</td></tr>
###xml 1446 1490 1446 1490 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Double-stranded oligonucleotides (for EMSAs)</bold>
###xml 1446 1490 1446 1490 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"><bold>Double-stranded oligonucleotides (for EMSAs)</bold></td>
###xml 1490 1490 1490 1490 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"/>
###xml 1446 1490 1446 1490 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1"><bold>Double-stranded oligonucleotides (for EMSAs)</bold></td><td rowspan="1" colspan="1"/></tr>
###xml 1490 1498 1490 1498 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">E-boxcon</td>
###xml 1498 1531 1498 1531 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">5&#8242;-ATCTGTATCACGTGTGTAGTCGTGATG-3&#8242;</td>
###xml 1490 1531 1490 1531 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1">E-boxcon</td><td rowspan="1" colspan="1">5&#8242;-ATCTGTATCACGTGTGTAGTCGTGATG-3&#8242;</td></tr>
###xml 1531 1534 1531 1534 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 1531 1540 1531 1540 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"><italic>FXN</italic> E-box</td>
###xml 1540 1576 1540 1576 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">5&#8242;-GAACTTCCCACACGTGTTATTTGGCCCACA-3&#8242;</td>
###xml 1531 1576 1531 1576 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1"><italic>FXN</italic> E-box</td><td rowspan="1" colspan="1">5&#8242;-GAACTTCCCACACGTGTTATTTGGCCCACA-3&#8242;</td></tr>
###xml 1576 1579 1576 1579 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 1576 1590 1576 1586 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"><italic>FXN</italic> E-box&#916;</td>
###xml 1590 1616 1586 1612 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">5&#8242;-ACACGTGTTATTTGGCCCAC-3&#8242;</td>
###xml 1576 1616 1576 1612 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1"><italic>FXN</italic> E-box&#916;</td><td rowspan="1" colspan="1">5&#8242;-ACACGTGTTATTTGGCCCAC-3&#8242;</td></tr>
###xml 976 1616 976 1612 <tbody xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" align="left"><tr><td rowspan="1" colspan="1"><bold>Primers</bold></td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"><italic>FXN</italic>Me74-F</td><td rowspan="1" colspan="1">5&#8242;-TTTTTCTCGAGAATAAGGTATAGAGAGGTTAATTAATTTGTTTTTTGGTTATA-3&#8242;</td></tr><tr><td rowspan="1" colspan="1"><italic>FXN</italic>Me956-R</td><td rowspan="1" colspan="1">5&#8242;-TTTTTGAATTCCCCTCCACCAACCTACCCTACCTTC-3&#8242;</td></tr><tr><td rowspan="1" colspan="1"><italic>FXN</italic>Me1212-F</td><td rowspan="1" colspan="1">5&#8242;-TTTTTCTCGAGGAGGTGAAATTTTTAGAGTTGTAGAATAGTTAGAGTAGTAG-3&#8242;</td></tr><tr><td rowspan="1" colspan="1"><italic>FXN</italic>Me1930-R</td><td rowspan="1" colspan="1">5&#8242;-TTTTTGAATTCACCTCCCAAAATACTAAAATTATAAACATAAACCA-3&#8242;</td></tr><tr><td rowspan="1" colspan="1"><italic>FXN</italic>PrF</td><td rowspan="1" colspan="1">5&#8242;-TTTTTTACGCGTGCTATGATGGCCGGGCTGGAATGCTGTGGCTATTCACAG-3&#8242;</td></tr><tr><td rowspan="1" colspan="1"><italic>FXN</italic>-Luc-F1</td><td rowspan="1" colspan="1">5&#8242;-ACCGACATCGATGCGACCT-3&#8242;</td></tr><tr><td rowspan="1" colspan="1"><italic>FXN</italic>-Luc-R2</td><td rowspan="1" colspan="1">5&#8242;-TTGCTCTCCAGCGGTTCCATCTT-3&#8242;</td></tr><tr><td rowspan="1" colspan="1"><italic>FXN</italic>chip-QF1</td><td rowspan="1" colspan="1">5&#8242;-GCAAAGGCCAGGAAGGCGGA-3&#8242;</td></tr><tr><td rowspan="1" colspan="1"><italic>FXN</italic>chip-QR1</td><td rowspan="1" colspan="1">5&#8242;-ATGGCTTGGACGTGGCCTGC-3&#8242;</td></tr><tr><td rowspan="1" colspan="1"><bold>Double-stranded oligonucleotides (for EMSAs)</bold></td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">E-boxcon</td><td rowspan="1" colspan="1">5&#8242;-ATCTGTATCACGTGTGTAGTCGTGATG-3&#8242;</td></tr><tr><td rowspan="1" colspan="1"><italic>FXN</italic> E-box</td><td rowspan="1" colspan="1">5&#8242;-GAACTTCCCACACGTGTTATTTGGCCCACA-3&#8242;</td></tr><tr><td rowspan="1" colspan="1"><italic>FXN</italic> E-box&#916;</td><td rowspan="1" colspan="1">5&#8242;-ACACGTGTTATTTGGCCCAC-3&#8242;</td></tr></tbody>
###xml 976 1616 976 1612 <table xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" frame="hsides" rules="groups"><tbody align="left"><tr><td rowspan="1" colspan="1"><bold>Primers</bold></td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"><italic>FXN</italic>Me74-F</td><td rowspan="1" colspan="1">5&#8242;-TTTTTCTCGAGAATAAGGTATAGAGAGGTTAATTAATTTGTTTTTTGGTTATA-3&#8242;</td></tr><tr><td rowspan="1" colspan="1"><italic>FXN</italic>Me956-R</td><td rowspan="1" colspan="1">5&#8242;-TTTTTGAATTCCCCTCCACCAACCTACCCTACCTTC-3&#8242;</td></tr><tr><td rowspan="1" colspan="1"><italic>FXN</italic>Me1212-F</td><td rowspan="1" colspan="1">5&#8242;-TTTTTCTCGAGGAGGTGAAATTTTTAGAGTTGTAGAATAGTTAGAGTAGTAG-3&#8242;</td></tr><tr><td rowspan="1" colspan="1"><italic>FXN</italic>Me1930-R</td><td rowspan="1" colspan="1">5&#8242;-TTTTTGAATTCACCTCCCAAAATACTAAAATTATAAACATAAACCA-3&#8242;</td></tr><tr><td rowspan="1" colspan="1"><italic>FXN</italic>PrF</td><td rowspan="1" colspan="1">5&#8242;-TTTTTTACGCGTGCTATGATGGCCGGGCTGGAATGCTGTGGCTATTCACAG-3&#8242;</td></tr><tr><td rowspan="1" colspan="1"><italic>FXN</italic>-Luc-F1</td><td rowspan="1" colspan="1">5&#8242;-ACCGACATCGATGCGACCT-3&#8242;</td></tr><tr><td rowspan="1" colspan="1"><italic>FXN</italic>-Luc-R2</td><td rowspan="1" colspan="1">5&#8242;-TTGCTCTCCAGCGGTTCCATCTT-3&#8242;</td></tr><tr><td rowspan="1" colspan="1"><italic>FXN</italic>chip-QF1</td><td rowspan="1" colspan="1">5&#8242;-GCAAAGGCCAGGAAGGCGGA-3&#8242;</td></tr><tr><td rowspan="1" colspan="1"><italic>FXN</italic>chip-QR1</td><td rowspan="1" colspan="1">5&#8242;-ATGGCTTGGACGTGGCCTGC-3&#8242;</td></tr><tr><td rowspan="1" colspan="1"><bold>Double-stranded oligonucleotides (for EMSAs)</bold></td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">E-boxcon</td><td rowspan="1" colspan="1">5&#8242;-ATCTGTATCACGTGTGTAGTCGTGATG-3&#8242;</td></tr><tr><td rowspan="1" colspan="1"><italic>FXN</italic> E-box</td><td rowspan="1" colspan="1">5&#8242;-GAACTTCCCACACGTGTTATTTGGCCCACA-3&#8242;</td></tr><tr><td rowspan="1" colspan="1"><italic>FXN</italic> E-box&#916;</td><td rowspan="1" colspan="1">5&#8242;-ACACGTGTTATTTGGCCCAC-3&#8242;</td></tr></tbody></table>
###xml 926 1616 926 1612 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="T1" position="float"><label>Table 1.</label><caption><p textid="13">Oligonucleotides used in these experiments</p></caption><table frame="hsides" rules="groups"><tbody align="left"><tr><td rowspan="1" colspan="1"><bold>Primers</bold></td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"><italic>FXN</italic>Me74-F</td><td rowspan="1" colspan="1">5&#8242;-TTTTTCTCGAGAATAAGGTATAGAGAGGTTAATTAATTTGTTTTTTGGTTATA-3&#8242;</td></tr><tr><td rowspan="1" colspan="1"><italic>FXN</italic>Me956-R</td><td rowspan="1" colspan="1">5&#8242;-TTTTTGAATTCCCCTCCACCAACCTACCCTACCTTC-3&#8242;</td></tr><tr><td rowspan="1" colspan="1"><italic>FXN</italic>Me1212-F</td><td rowspan="1" colspan="1">5&#8242;-TTTTTCTCGAGGAGGTGAAATTTTTAGAGTTGTAGAATAGTTAGAGTAGTAG-3&#8242;</td></tr><tr><td rowspan="1" colspan="1"><italic>FXN</italic>Me1930-R</td><td rowspan="1" colspan="1">5&#8242;-TTTTTGAATTCACCTCCCAAAATACTAAAATTATAAACATAAACCA-3&#8242;</td></tr><tr><td rowspan="1" colspan="1"><italic>FXN</italic>PrF</td><td rowspan="1" colspan="1">5&#8242;-TTTTTTACGCGTGCTATGATGGCCGGGCTGGAATGCTGTGGCTATTCACAG-3&#8242;</td></tr><tr><td rowspan="1" colspan="1"><italic>FXN</italic>-Luc-F1</td><td rowspan="1" colspan="1">5&#8242;-ACCGACATCGATGCGACCT-3&#8242;</td></tr><tr><td rowspan="1" colspan="1"><italic>FXN</italic>-Luc-R2</td><td rowspan="1" colspan="1">5&#8242;-TTGCTCTCCAGCGGTTCCATCTT-3&#8242;</td></tr><tr><td rowspan="1" colspan="1"><italic>FXN</italic>chip-QF1</td><td rowspan="1" colspan="1">5&#8242;-GCAAAGGCCAGGAAGGCGGA-3&#8242;</td></tr><tr><td rowspan="1" colspan="1"><italic>FXN</italic>chip-QR1</td><td rowspan="1" colspan="1">5&#8242;-ATGGCTTGGACGTGGCCTGC-3&#8242;</td></tr><tr><td rowspan="1" colspan="1"><bold>Double-stranded oligonucleotides (for EMSAs)</bold></td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">E-boxcon</td><td rowspan="1" colspan="1">5&#8242;-ATCTGTATCACGTGTGTAGTCGTGATG-3&#8242;</td></tr><tr><td rowspan="1" colspan="1"><italic>FXN</italic> E-box</td><td rowspan="1" colspan="1">5&#8242;-GAACTTCCCACACGTGTTATTTGGCCCACA-3&#8242;</td></tr><tr><td rowspan="1" colspan="1"><italic>FXN</italic> E-box&#916;</td><td rowspan="1" colspan="1">5&#8242;-ACACGTGTTATTTGGCCCAC-3&#8242;</td></tr></tbody></table></table-wrap>
###xml 286 290 <span type="species:ncbi:9913">calf</span>
Lymphoblasts from individuals without FRDA (GM06895, GM06865, GM06891 and GM09145), and those with FRDA (GM04079, GM15850, GM16207, GM16209 and GM16243) were obtained from the Coriell Cell Repository (Camden, NJ). Lymphoblasts were grown in RPMI 1640 medium supplemented with 10% fetal calf serum under standard conditions (Invitrogen Life Technologies Inc., Carlsbad, CA). Genomic DNA was prepared from these cell lines using standard procedures. The FXN repeat numbers in normal individuals were determined as described earlier (3,16). DNA obtained from fresh blood of affected and unaffected individuals was a kind gift of Dr Ed Grabczyk, Louisiana State University. The plasmid construct expressing the M.eco72I methylase was a kind gift of Fermentas AB (Vilnius, Lithuania). The primers and double-stranded oligonucleotides used were synthesized by Integrated DNA Technologies (Coralville, IA) and are listed in Table 1. Table 1.Oligonucleotides used in these experimentsPrimersFXNMe74-F5'-TTTTTCTCGAGAATAAGGTATAGAGAGGTTAATTAATTTGTTTTTTGGTTATA-3'FXNMe956-R5'-TTTTTGAATTCCCCTCCACCAACCTACCCTACCTTC-3'FXNMe1212-F5'-TTTTTCTCGAGGAGGTGAAATTTTTAGAGTTGTAGAATAGTTAGAGTAGTAG-3'FXNMe1930-R5'-TTTTTGAATTCACCTCCCAAAATACTAAAATTATAAACATAAACCA-3'FXNPrF5'-TTTTTTACGCGTGCTATGATGGCCGGGCTGGAATGCTGTGGCTATTCACAG-3'FXN-Luc-F15'-ACCGACATCGATGCGACCT-3'FXN-Luc-R25'-TTGCTCTCCAGCGGTTCCATCTT-3'FXNchip-QF15'-GCAAAGGCCAGGAAGGCGGA-3'FXNchip-QR15'-ATGGCTTGGACGTGGCCTGC-3'Double-stranded oligonucleotides (for EMSAs)E-boxcon5'-ATCTGTATCACGTGTGTAGTCGTGATG-3'FXN E-box5'-GAACTTCCCACACGTGTTATTTGGCCCACA-3'FXN E-boxDelta5'-ACACGTGTTATTTGGCCCAC-3'
###end p 12
###begin p 13
Oligonucleotides used in these experiments
###end p 13
###begin title 14
DNA methylation analysis
###end title 14
###begin p 15
###xml 323 326 317 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 337 340 331 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 388 391 382 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 436 439 430 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 452 455 446 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
Genomic DNA from cell lines of four unaffected and four affected individuals was bisulphite modified according to standard procedures except that the bisulphite treatment was carried out overnight at 55degreesC. The methylation status of the promoter and intron 1 were examined. The promoter was analyzed using the primers FXNMe74-F and FXNMe956-R. The region 5' of the GAA repeat in the FXN gene was amplified by PCR using the primers FXNMe1212-F and FXNMe1930-R. The PCR fragments were gel purified, digested with XhoI and EcoRI, cloned into pBS SK+ (Stratagene, La Jolla, CA, USA) and sequenced. Five clones from each individual were sequenced. The data for each population was pooled and the frequency with which each residue was methylated was then plotted along with the standard deviation.
###end p 15
###begin title 16
Reporter assays
###end title 16
###begin p 17
###xml 11 14 11 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 156 159 156 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 311 314 311 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 809 812 809 812 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 835 838 835 838 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 905 908 905 908 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 1002 1005 1002 1005 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 1092 1095 1092 1095 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 1110 1113 1110 1113 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 1192 1195 1192 1195 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 1438 1454 1438 1454 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Escherichia coli</italic>
###xml 1462 1464 1462 1464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 1520 1522 1520 1522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 1745 1747 1745 1747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 2013 2015 2009 2011 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 709 714 <span type="species:ncbi:9606">human</span>
###xml 1438 1454 <span type="species:ncbi:562">Escherichia coli</span>
###xml 1698 1703 <span type="species:ncbi:10090">mouse</span>
The primer FXNPrF was used as the forward primer for all constructs. This primer has an MluI site at its 5' end and primes 1118 bp upstream of the start of FXN translation. Each of the reverse primers contained the splice acceptor site from the 3' end of intron 1 and an NcoI site and were designed so that the FXN coding sequence in exon 1 would be translated in frame with the luciferase open reading frame from pGL3-Basic (Promega, Madison, WI, USA). After PCR amplification, the gel-purified fragment was digested with MluI and NcoI and cloned into pGL3-Basic. The numbers in the construct names are based on the location of the reverse primer in the chromosome 9 sequence from the May 2004 freeze of the human genome in the UCSC database with the numbering starting at 68 800 000. Thus the 3' end of the FXN sequence in construct FXN80940 corresponds to base 68 880 940 in the chromosome 9 sequence. FXN81423 contains 1006 bases from the 5' end of intron 1 terminating at position 68 881 423, and FXN81658 contains the first 1241 bases of intron 1 and terminates at position 68 881 658. FXN E-box/Mt+ and FXN E-box/Mt- clones were generated using reverse primers that contain either the FXN intron E-box/Mt sequence or the sequence immediately downstream of this region. The resultant clones differ only by eight bases. The second C in the E-box core sequence 5'-CACGTG-3' can be methylated by M.eco72I, a DNA methyltransferase from Escherichia coli RFL72 (17). Methylation was carried out as previously described (18), and the extent of methylation checked by digestion with PmlI, a restriction enzyme whose cleavage is blocked by M.eco72I methylation. Reporter assays were carried out using mouse C2C12 myoblasts as previously described (19). To assess any differences in the RNA stability of these constructs, cells were treated 24 h post-transfection with 5 microg/ml actinomycin D. RNA and protein samples were collected after 8 h. The luciferase protein levels were determined as previously described (19). The luciferase mRNA levels were determined by real-time PCR as described below. The RNA and protein values after 8 h of actinomycin treatment were calculated as the percentage of the values obtained at 0 h.
###end p 17
###begin title 18
Electrophoretic mobility shift assays (EMSAs)
###end title 18
###begin p 19
###xml 34 37 34 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 75 77 71 73 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 672 675 657 660 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 686 689 671 674 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
A double-stranded oligonucleotide FXN E-box was radiolabeled using [gamma-P32] ATP (MP Biomedicals, Solon, OH) and T4 polynucleotide kinase (New England Biolabs, Beverly, MA, USA) according to standard procedures. Nuclear extracts were prepared from C2C12 cells using NE-PER Nuclear Extraction Reagents (Pierce, Rockford, IL, USA) according to the supplier's instructions. Binding was carried out at 20degreesC for 30 min in 30 mul of reaction buffer containing 5 microg of nuclear extract, 25 mM HEPES (pH 7.5), 100 mM NaCl, 1 mM EDTA and 4 mM DTT with 0.005 pmol of labeled probe. A 1000-fold molar excess of oligonucleotides containing a consensus E-box, E-boxcon, the FXN E-box and FXN E-boxDelta were used as competitors in this assay. The samples were subjected to electrophoresis on 5% native polyacrylamide (60:1, acrylamide:bisacrylamide) gels.
###end p 19
###begin title 20
Real-time RT-PCR
###end title 20
###begin p 21
###xml 313 321 304 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN, GUS</italic>
###xml 615 618 604 607 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 630 633 619 622 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
Total RNA was isolated from the cell lines using Trizol (Invitrogen Life Technologies Inc.) and reverse transcribed using SuperScripttrade mark III RT First strand synthesis system for RT-PCR (Invitrogen Life Technologies Inc.), as per the manufacturer's instructions. Real-time PCRs for measuring the endogenous FXN, GUS and 18S RNA were carried out using an ABI 7500 FAST PCR system (Applied Biosystems, Foster City, CA, USA) and appropriate Taqman probe primer mixes (Applied Biosystems). Quantitation of luciferase mRNA was carried out using Power SYBR(R) Green PCR mix (Applied Biosystems) and the primer pair FXN-Luc-F1 and FXN-Luc-R2 which amplifies across the intron between the Frataxin exon 1 and the luciferase coding sequence.
###end p 21
###begin title 22
Chromatin immunoprecipitation assays
###end title 22
###begin p 23
###xml 972 973 960 961 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 1211 1214 1193 1196 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 1375 1378 1355 1358 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 1391 1394 1371 1374 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 56 59 <span type="species:ncbi:9685">Cat</span>
###xml 132 138 <span type="species:ncbi:9986">rabbit</span>
The anti-dimethyl-Histone H3 (Lys9) (H3K9me2) antibody (Cat. no. 07-441) was purchased from Upstate (Charlottesville, VA, USA). The rabbit preimmune serum was purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). The ChIP assay kit from Upstate was used according to the manufacturer's instructions with slight modifications. Briefly, cells were cross-linked in RPMI medium 1640 with 1% formaldehyde at 23degreesC for 5 min. The cells were washed in PBS and lysed in a buffer containing 1% SDS, 10 mM EDTA and 50 mM Tris-HCl pH 8.0. The chromatin from lysed cells was sonicated to lengths between 200 and 1000 bp using a Bioruptor sonicator (Diagenode, Philadelphia, PA, USA) and the cell debris was removed by centrifugation. The sonicated lysates were precleared and incubated with either preimmune serum or the anti-H3K9Me2 antibody at 4degreesC overnight. The immunocomplexes were recovered by Protein A agarose, washed and eluted in 1% SDS, 0.1 M NaHCO3 and the crosslinking reversed by incubation at 65degreesC for 4 h in 200 mM NaCl. The samples were phenol: chloroform extracted and ethanol precipitated in the presence of Pelletpaint (EMD Biosciences, San Diego, CA, USA). The amount of FXN DNA immunoprecipitated was determined using quantitative real-time PCR using Power SYBR(R) green PCR master mix (Applied Biosystems). The PCR primers used were FXNchip-QF1 and FXNchip-QR1. The ChIP experiments were performed in triplicate and each PCR reaction was done in duplicate. The immunoprecipitated DNA was normalized to the amount of input DNA and plotted as the fold enrichment over the preimmune serum (IgG).
###end p 23
###begin title 24
RESULTS AND DISCUSSION
###end title 24
###begin p 25
###xml 87 90 87 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 149 152 149 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 172 174 172 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 255 258 255 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 351 356 351 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10 B11 B12 B13">10&#8211;13</xref>
###xml 547 550 547 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 568 576 568 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 611 614 611 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 721 724 721 724 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 1022 1024 1022 1024 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 1079 1082 1079 1082 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 1123 1125 1123 1125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 1128 1137 1128 1137 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1.</label>
###xml 1171 1172 1171 1172 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 1226 1229 1226 1229 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 1263 1266 1263 1266 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 1329 1332 1329 1332 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 1509 1512 1509 1512 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 1804 1805 1804 1805 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 1934 1937 1934 1937 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 1137 2249 1137 2249 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="26">The 5&#8242; end of the frataxin gene. (<bold>A</bold>) Schematic representation of the 5&#8242; end of the human <italic>FXN</italic> gene showing the location of the <italic>FXN</italic> repeat relative to the other repeated DNA elements and to the <italic>FXN</italic> promoter. The 5&#8242; end of the region depicted here corresponds to base 68&#8201;878&#8201;851 of chromosome 9 in the 2004 build of the UCSC human DNA sequence database. The beginning of the <italic>FXN</italic> repeat corresponds to base 68&#8201;881&#8201;758 of this sequence. The numbers 3, 6 and 13 refer to those CpG residues that are protected from methylation in cells from unaffected individuals but that are methylated in FRDA cells. These residues correspond to the Cs marked with asterisks in panel B. (<bold>B</bold>) The sequence of region of intron 1 analyzed by bisulfite mapping showing an alignment of the human with chimpanzee and macaque <italic>FXN</italic> genes. The bold numbers 1&#8211;15 indicate the 15 methylatable C residues that were analyzed. The boxed sequences indicate interspersed repeated DNA elements. The dotted gray line above the sequence indicates the core muscle-specific Mt-binding site. The solid gray line below the sequence marks the core E-box site.</p>
###xml 1137 2249 1137 2249 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="26">The 5&#8242; end of the frataxin gene. (<bold>A</bold>) Schematic representation of the 5&#8242; end of the human <italic>FXN</italic> gene showing the location of the <italic>FXN</italic> repeat relative to the other repeated DNA elements and to the <italic>FXN</italic> promoter. The 5&#8242; end of the region depicted here corresponds to base 68&#8201;878&#8201;851 of chromosome 9 in the 2004 build of the UCSC human DNA sequence database. The beginning of the <italic>FXN</italic> repeat corresponds to base 68&#8201;881&#8201;758 of this sequence. The numbers 3, 6 and 13 refer to those CpG residues that are protected from methylation in cells from unaffected individuals but that are methylated in FRDA cells. These residues correspond to the Cs marked with asterisks in panel B. (<bold>B</bold>) The sequence of region of intron 1 analyzed by bisulfite mapping showing an alignment of the human with chimpanzee and macaque <italic>FXN</italic> genes. The bold numbers 1&#8211;15 indicate the 15 methylatable C residues that were analyzed. The boxed sequences indicate interspersed repeated DNA elements. The dotted gray line above the sequence indicates the core muscle-specific Mt-binding site. The solid gray line below the sequence marks the core E-box site.</p></caption>
###xml 2249 2249 2249 2249 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkm271f1"/>
###xml 1128 2249 1128 2249 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F1" position="float"><label>Figure 1.</label><caption><p textid="26">The 5&#8242; end of the frataxin gene. (<bold>A</bold>) Schematic representation of the 5&#8242; end of the human <italic>FXN</italic> gene showing the location of the <italic>FXN</italic> repeat relative to the other repeated DNA elements and to the <italic>FXN</italic> promoter. The 5&#8242; end of the region depicted here corresponds to base 68&#8201;878&#8201;851 of chromosome 9 in the 2004 build of the UCSC human DNA sequence database. The beginning of the <italic>FXN</italic> repeat corresponds to base 68&#8201;881&#8201;758 of this sequence. The numbers 3, 6 and 13 refer to those CpG residues that are protected from methylation in cells from unaffected individuals but that are methylated in FRDA cells. These residues correspond to the Cs marked with asterisks in panel B. (<bold>B</bold>) The sequence of region of intron 1 analyzed by bisulfite mapping showing an alignment of the human with chimpanzee and macaque <italic>FXN</italic> genes. The bold numbers 1&#8211;15 indicate the 15 methylatable C residues that were analyzed. The boxed sequences indicate interspersed repeated DNA elements. The dotted gray line above the sequence indicates the core muscle-specific Mt-binding site. The solid gray line below the sequence marks the core E-box site.</p></caption><graphic xlink:href="gkm271f1"/></fig>
###xml 1220 1225 <span type="species:ncbi:9606">human</span>
###xml 1459 1464 <span type="species:ncbi:9606">human</span>
###xml 1900 1905 <span type="species:ncbi:9606">human</span>
###xml 1911 1921 <span type="species:ncbi:9598">chimpanzee</span>
We have previously analyzed the region upstream of the transcription start site of the FXN gene and identified the regulatory elements important for FXN promoter activity (19). However, almost nothing was known about the region of intron 1 containing the FXN repeat. Since sequences important for promoter activity can be located in the first intron (10-13) and the sequences closest to the repeat are the ones most likely to be affected by repeat expansion, we set out to examine this region in some detail. The organization of the 5' end of the FXN gene is shown in Figure 1A. Intron 1 is 10 436 bp long. The FXN repeat is located 1340 bp from the beginning of the intron. The region of intron 1 between exon 1 and the FXN repeat contains three interspersed repeated DNA elements. This includes a member of the ancient MIRb family of repeated DNA elements that is thought to have been active in transposition before the mammalian radiation, Charlie8, a member of the primate-specific MER1 (medium reiteration 1) family (20) and the first half of the Alu element from which the FXN repeat is thought to have been derived (21). Figure 1.The 5' end of the frataxin gene. (A) Schematic representation of the 5' end of the human FXN gene showing the location of the FXN repeat relative to the other repeated DNA elements and to the FXN promoter. The 5' end of the region depicted here corresponds to base 68 878 851 of chromosome 9 in the 2004 build of the UCSC human DNA sequence database. The beginning of the FXN repeat corresponds to base 68 881 758 of this sequence. The numbers 3, 6 and 13 refer to those CpG residues that are protected from methylation in cells from unaffected individuals but that are methylated in FRDA cells. These residues correspond to the Cs marked with asterisks in panel B. (B) The sequence of region of intron 1 analyzed by bisulfite mapping showing an alignment of the human with chimpanzee and macaque FXN genes. The bold numbers 1-15 indicate the 15 methylatable C residues that were analyzed. The boxed sequences indicate interspersed repeated DNA elements. The dotted gray line above the sequence indicates the core muscle-specific Mt-binding site. The solid gray line below the sequence marks the core E-box site.
###end p 25
###begin p 26
###xml 34 35 34 35 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 89 92 89 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 126 129 126 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 192 195 192 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 372 375 372 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 667 668 667 668 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 797 800 797 800 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 83 88 <span type="species:ncbi:9606">human</span>
###xml 322 327 <span type="species:ncbi:9606">human</span>
###xml 763 768 <span type="species:ncbi:9606">human</span>
###xml 774 784 <span type="species:ncbi:9598">chimpanzee</span>
The 5' end of the frataxin gene. (A) Schematic representation of the 5' end of the human FXN gene showing the location of the FXN repeat relative to the other repeated DNA elements and to the FXN promoter. The 5' end of the region depicted here corresponds to base 68 878 851 of chromosome 9 in the 2004 build of the UCSC human DNA sequence database. The beginning of the FXN repeat corresponds to base 68 881 758 of this sequence. The numbers 3, 6 and 13 refer to those CpG residues that are protected from methylation in cells from unaffected individuals but that are methylated in FRDA cells. These residues correspond to the Cs marked with asterisks in panel B. (B) The sequence of region of intron 1 analyzed by bisulfite mapping showing an alignment of the human with chimpanzee and macaque FXN genes. The bold numbers 1-15 indicate the 15 methylatable C residues that were analyzed. The boxed sequences indicate interspersed repeated DNA elements. The dotted gray line above the sequence indicates the core muscle-specific Mt-binding site. The solid gray line below the sequence marks the core E-box site.
###end p 26
###begin title 27
Intron 1 in affected and unaffected individuals show differences in DNA methylation
###end title 27
###begin p 28
###xml 101 104 101 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 114 115 114 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 198 201 198 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 362 370 362 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 528 536 516 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 851 853 839 841 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 1189 1197 1177 1185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 1942 1951 1930 1939 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2.</label>
###xml 2013 2016 2001 2004 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 1951 2551 1939 2539 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="29">Methylation status of 15 CpG residues in the region 5&#8242; of the <italic>FXN</italic> repeat in cells from unaffected and affected individuals. DNA from lymphoblastoid cell lines from four unaffected individuals and four individuals with FRDA was bisulphite modified and cloned as described in the Materials and Methods section. The numbers below the bars indicate the residue number using the same numbering convention used in Figure 1. The gray arrows indicate the three residues that are frequently methylated in affected individuals but that are very infrequently methylated, if at all, in the unaffected population.</p>
###xml 1951 2551 1939 2539 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="29">Methylation status of 15 CpG residues in the region 5&#8242; of the <italic>FXN</italic> repeat in cells from unaffected and affected individuals. DNA from lymphoblastoid cell lines from four unaffected individuals and four individuals with FRDA was bisulphite modified and cloned as described in the Materials and Methods section. The numbers below the bars indicate the residue number using the same numbering convention used in Figure 1. The gray arrows indicate the three residues that are frequently methylated in affected individuals but that are very infrequently methylated, if at all, in the unaffected population.</p></caption>
###xml 2551 2551 2539 2539 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkm271f2"/>
###xml 1942 2551 1930 2539 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F2" position="float"><label>Figure 2.</label><caption><p textid="29">Methylation status of 15 CpG residues in the region 5&#8242; of the <italic>FXN</italic> repeat in cells from unaffected and affected individuals. DNA from lymphoblastoid cell lines from four unaffected individuals and four individuals with FRDA was bisulphite modified and cloned as described in the Materials and Methods section. The numbers below the bars indicate the residue number using the same numbering convention used in Figure 1. The gray arrows indicate the three residues that are frequently methylated in affected individuals but that are very infrequently methylated, if at all, in the unaffected population.</p></caption><graphic xlink:href="gkm271f2"/></fig>
###xml 1103 1111 <span type="species:ncbi:9606">patients</span>
Since repeat-mediated epigenetic changes have been suggested to occur in regions containing expanded FXN repeats (8), we examined the methylation changes in the sequence immediately upstream of the FXN repeat. Bisulfite analysis demonstrates that a number of CpG residues were methylated in cell lines from both individuals with FRDA and unaffected individuals (Figure 2). However, the average methylation density was approximately50% higher in cells from affected individuals (compare the heights of the black and gray bars in Figure 2). This reflects, in part, the fact that the methylation density decreased more slowly 5' of the repeat tract in these cells. The basal level of methylation seen in unaffected individuals may be due to methylation spreading from the downstream Alu element since these elements are themselves frequently methylated (22). In addition to an overall increase in methylation in FRDA cells, certain residues were much more likely to be methylated in these cells than in those without the disease. For example residues 3, 6, and 13 are methylated in 75-100% of alleles from patients, while they were completely free from methylation in unaffected individuals (Figure 2). DNA from fresh blood of four unrelated individuals with FRDA showed a similar methylation of residues 3, 6 and 13 to DNA (data not shown), suggesting that this methylation is not an artifact of the transformation process. Thus normal alleles seem to have a naturally occurring 'methylation footprint' that is absent from FRDA alleles. The elevated level of methylation seen in FRDA cells disappeared 5' of residue 3 with overall levels of methylation in both populations falling to 20% at residue 1. Thus the repeat-mediated increase in DNA methylation is limited to the region immediately adjacent to the repeat. This conclusion is consistent with the lack of any DNA methylation in the promoter of either population group (data not shown). Figure 2.Methylation status of 15 CpG residues in the region 5' of the FXN repeat in cells from unaffected and affected individuals. DNA from lymphoblastoid cell lines from four unaffected individuals and four individuals with FRDA was bisulphite modified and cloned as described in the Materials and Methods section. The numbers below the bars indicate the residue number using the same numbering convention used in Figure 1. The gray arrows indicate the three residues that are frequently methylated in affected individuals but that are very infrequently methylated, if at all, in the unaffected population.
###end p 28
###begin p 29
###xml 62 65 62 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
Methylation status of 15 CpG residues in the region 5' of the FXN repeat in cells from unaffected and affected individuals. DNA from lymphoblastoid cell lines from four unaffected individuals and four individuals with FRDA was bisulphite modified and cloned as described in the Materials and Methods section. The numbers below the bars indicate the residue number using the same numbering convention used in Figure 1. The gray arrows indicate the three residues that are frequently methylated in affected individuals but that are very infrequently methylated, if at all, in the unaffected population.
###end p 29
###begin title 30
Intron 1 contributes to FXN promoter activity
###end title 30
###begin p 31
###xml 279 282 279 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 690 698 690 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 731 734 731 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 814 817 814 817 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 1046 1049 1034 1037 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 1103 1106 1091 1094 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 1242 1245 1218 1221 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 1252 1260 1228 1236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 1276 1279 1252 1255 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 1317 1320 1293 1296 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 1399 1402 1375 1378 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 1429 1437 1405 1413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 1453 1456 1429 1432 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 1466 1469 1442 1445 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 1992 1995 1968 1971 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 2015 2024 1991 2000 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3.</label>
###xml 2100 2103 2076 2079 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 2115 2118 2091 2094 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A&#8211;C</bold>
###xml 2451 2454 2427 2430 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 2481 2484 2457 2460 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 2589 2592 2565 2568 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 2844 2845 2820 2821 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 2901 2904 2877 2880 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 2911 2914 2887 2890 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 2921 2924 2897 2900 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 2938 2941 2914 2917 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 2024 3178 2000 3154 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="32">The effect of different lengths of intron 1 sequence on the activity of the <italic>FXN</italic> promoter. (<bold>A&#8211;C</bold>). Luciferase activities of constructs containing different amounts of intron 1. Constructs containing the promoter, exon 1 and different lengths of intron 1 sequence were transfected into mouse myoblasts as described in the Materials and Methods section. The dotted lines demarcate deleted regions. The suffix &#8216;Me&#8217; in the construct <italic>FXN</italic>81658Me indicates that the <italic>FXN</italic>81658 construct was specifically methylated at the E-box/Mt-binding site. The luciferase levels from the <italic>FXN</italic> reporter constructs were normalized to luciferase levels from the pRLNull vector and expressed as a percentage of the normalized luciferase activity of the full-length construct. The data are an average of three independent transfection experiments. (<bold>D</bold>) Actinomycin D treatment of cells transfected with the <italic>FXN</italic>81658, <italic>FXN</italic>81423, <italic>FXN</italic>E-box/Mt+ and <italic>FXN</italic>E-box/Mt- constructs. The values for the luciferase protein and mRNA after exposure to Actinomycin D for 8&#8201;h are shown expressed as a percentage of the values at 0&#8201;h. The data shown represent the average of three independent experiments.</p>
###xml 2024 3178 2000 3154 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="32">The effect of different lengths of intron 1 sequence on the activity of the <italic>FXN</italic> promoter. (<bold>A&#8211;C</bold>). Luciferase activities of constructs containing different amounts of intron 1. Constructs containing the promoter, exon 1 and different lengths of intron 1 sequence were transfected into mouse myoblasts as described in the Materials and Methods section. The dotted lines demarcate deleted regions. The suffix &#8216;Me&#8217; in the construct <italic>FXN</italic>81658Me indicates that the <italic>FXN</italic>81658 construct was specifically methylated at the E-box/Mt-binding site. The luciferase levels from the <italic>FXN</italic> reporter constructs were normalized to luciferase levels from the pRLNull vector and expressed as a percentage of the normalized luciferase activity of the full-length construct. The data are an average of three independent transfection experiments. (<bold>D</bold>) Actinomycin D treatment of cells transfected with the <italic>FXN</italic>81658, <italic>FXN</italic>81423, <italic>FXN</italic>E-box/Mt+ and <italic>FXN</italic>E-box/Mt- constructs. The values for the luciferase protein and mRNA after exposure to Actinomycin D for 8&#8201;h are shown expressed as a percentage of the values at 0&#8201;h. The data shown represent the average of three independent experiments.</p></caption>
###xml 3178 3178 3154 3154 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkm271f3"/>
###xml 2015 3178 1991 3154 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F3" position="float"><label>Figure 3.</label><caption><p textid="32">The effect of different lengths of intron 1 sequence on the activity of the <italic>FXN</italic> promoter. (<bold>A&#8211;C</bold>). Luciferase activities of constructs containing different amounts of intron 1. Constructs containing the promoter, exon 1 and different lengths of intron 1 sequence were transfected into mouse myoblasts as described in the Materials and Methods section. The dotted lines demarcate deleted regions. The suffix &#8216;Me&#8217; in the construct <italic>FXN</italic>81658Me indicates that the <italic>FXN</italic>81658 construct was specifically methylated at the E-box/Mt-binding site. The luciferase levels from the <italic>FXN</italic> reporter constructs were normalized to luciferase levels from the pRLNull vector and expressed as a percentage of the normalized luciferase activity of the full-length construct. The data are an average of three independent transfection experiments. (<bold>D</bold>) Actinomycin D treatment of cells transfected with the <italic>FXN</italic>81658, <italic>FXN</italic>81423, <italic>FXN</italic>E-box/Mt+ and <italic>FXN</italic>E-box/Mt- constructs. The values for the luciferase protein and mRNA after exposure to Actinomycin D for 8&#8201;h are shown expressed as a percentage of the values at 0&#8201;h. The data shown represent the average of three independent experiments.</p></caption><graphic xlink:href="gkm271f3"/></fig>
###xml 655 660 <span type="species:ncbi:10090">mouse</span>
###xml 2307 2312 <span type="species:ncbi:10090">mouse</span>
The methylation 'footprints' at residues 3, 6 and 13 in unaffected individuals could reflect either the existence of positioned nucleosomes or binding of sequence-specific DNA-binding proteins. If the latter were true, we might expect that deletion of these regions could affect FXN promoter activity in transient transfection assays. We therefore generated reporter constructs containing the promoter, exon 1, and various lengths of intron 1. Downstream of the intron 1 sequence in each construct was the branch and splice acceptor sites from the end of intron 1, and the luciferase coding sequence. The results of transfections of these constructs into mouse C2C12 myoblasts are shown in Figure 3A. The longest construct tested, FXN81658 contained the region of intron 1 from the end of exon 1 to just 5' of the FXN repeat that encompasses all three protected residues. This construct gave the highest luciferase activities of all the constructs tested with an activity that was approximately45-fold above that of the empty vector. A construct FXN81423 that terminated 235 bases 5' of the sequence in FXN81658, and therefore that lacked residue 13, had a luciferase activity that was only approximately10% that of the full length construct FXN81658 (Figure 3A). A construct FXN80940 that terminated 718 bases 5' of FXN81423, and thus lacked residue 3 and 6 had an activity very similar to that of FXN81423. As can be seen from Figure 3D, treatment of FXN81658 and FXN81423 transfected cells with the transcription inhibitor Actinomycin D resulted in very similar levels of luciferase protein and mRNA after 8 h of treatment. This suggests that the absolute difference in luciferase activity between the two constructs reflects differences in transcription rates rather than differences in RNA stability. Thus, it is likely that the 235 bp region of intron 1 containing residue 13 has a binding site for one or more transcription factors that make a significant positive contribution to the FXN promoter activity. Figure 3.The effect of different lengths of intron 1 sequence on the activity of the FXN promoter. (A-C). Luciferase activities of constructs containing different amounts of intron 1. Constructs containing the promoter, exon 1 and different lengths of intron 1 sequence were transfected into mouse myoblasts as described in the Materials and Methods section. The dotted lines demarcate deleted regions. The suffix 'Me' in the construct FXN81658Me indicates that the FXN81658 construct was specifically methylated at the E-box/Mt-binding site. The luciferase levels from the FXN reporter constructs were normalized to luciferase levels from the pRLNull vector and expressed as a percentage of the normalized luciferase activity of the full-length construct. The data are an average of three independent transfection experiments. (D) Actinomycin D treatment of cells transfected with the FXN81658, FXN81423, FXNE-box/Mt+ and FXNE-box/Mt- constructs. The values for the luciferase protein and mRNA after exposure to Actinomycin D for 8 h are shown expressed as a percentage of the values at 0 h. The data shown represent the average of three independent experiments.
###end p 31
###begin p 32
###xml 76 79 76 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 91 94 91 94 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A&#8211;C</bold>
###xml 427 430 427 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 457 460 457 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 565 568 565 568 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 820 821 820 821 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 877 880 877 880 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 887 890 887 890 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 897 900 897 900 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 914 917 914 917 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 283 288 <span type="species:ncbi:10090">mouse</span>
The effect of different lengths of intron 1 sequence on the activity of the FXN promoter. (A-C). Luciferase activities of constructs containing different amounts of intron 1. Constructs containing the promoter, exon 1 and different lengths of intron 1 sequence were transfected into mouse myoblasts as described in the Materials and Methods section. The dotted lines demarcate deleted regions. The suffix 'Me' in the construct FXN81658Me indicates that the FXN81658 construct was specifically methylated at the E-box/Mt-binding site. The luciferase levels from the FXN reporter constructs were normalized to luciferase levels from the pRLNull vector and expressed as a percentage of the normalized luciferase activity of the full-length construct. The data are an average of three independent transfection experiments. (D) Actinomycin D treatment of cells transfected with the FXN81658, FXN81423, FXNE-box/Mt+ and FXNE-box/Mt- constructs. The values for the luciferase protein and mRNA after exposure to Actinomycin D for 8 h are shown expressed as a percentage of the values at 0 h. The data shown represent the average of three independent experiments.
###end p 32
###begin p 33
###xml 529 537 529 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 561 569 561 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
Residue 13 is located within a putative E-box. This site overlaps with a binding site for the muscle specific Mt transcription factor. We generated two constructs differing only in eight bases. The first construct included the E-box/Mt-binding site and the second terminated just 5' of the E-box and was thus missing both sites. We measured the activity of these constructs in C2C12 cells. The construct lacking the E-box/Mt-binding site had a significantly lower luciferase activity than the construct containing these regions (Figure 3B). As can be seen from Figure 3D, Actinomycin D treatment had a similar effect on the yield of luciferase RNA and protein of both of these constructs. These findings support the idea that the original differences in luciferase activity we observe without Actinomycin D reflects a higher promoter activity for the construct with the E-box/Mt-binding site rather than enhanced mRNA stability.
###end p 33
###begin title 34
The E-box/Mt region binds transcription factors in extracts from muscle cells
###end title 34
###begin p 35
###xml 162 170 162 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 581 584 581 584 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 599 607 595 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 786 793 782 789 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 795 804 791 800 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4.</label>
###xml 878 881 874 877 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 984 987 980 983 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 1013 1016 1009 1012 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 1078 1081 1074 1077 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 804 1171 800 1163 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="36">Electrophoretic gel mobility shift analysis (EMSA) of proteins binding to <italic>FXN</italic> intron 1. EMSA was carried in the presence of molar excesses of E-boxcon, a canonical E-box sequence, <italic>FXN</italic> E-box which contains the <italic>FXN</italic> E-box together with the muscle-specific Mt-binding site, and <italic>FXN</italic> E-Box&#916; which contains the 3&#8242; end of the E-box together with the full Mt-binding site.</p>
###xml 804 1171 800 1163 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="36">Electrophoretic gel mobility shift analysis (EMSA) of proteins binding to <italic>FXN</italic> intron 1. EMSA was carried in the presence of molar excesses of E-boxcon, a canonical E-box sequence, <italic>FXN</italic> E-box which contains the <italic>FXN</italic> E-box together with the muscle-specific Mt-binding site, and <italic>FXN</italic> E-Box&#916; which contains the 3&#8242; end of the E-box together with the full Mt-binding site.</p></caption>
###xml 1171 1171 1163 1163 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkm271f4"/>
###xml 795 1171 791 1163 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F4" position="float"><label>Figure 4.</label><caption><p textid="36">Electrophoretic gel mobility shift analysis (EMSA) of proteins binding to <italic>FXN</italic> intron 1. EMSA was carried in the presence of molar excesses of E-boxcon, a canonical E-box sequence, <italic>FXN</italic> E-box which contains the <italic>FXN</italic> E-box together with the muscle-specific Mt-binding site, and <italic>FXN</italic> E-Box&#916; which contains the 3&#8242; end of the E-box together with the full Mt-binding site.</p></caption><graphic xlink:href="gkm271f4"/></fig>
Three protein-DNA complexes were found in electrophoretic mobility shift assays with C2C12 cells using the E-box/Mt region as a probe (complexes I, II and III in Figure 4, lane 2). Complexes I and II could be competed out by addition of E-boxcon, an oligonucleotide that contains a consensus E-box-binding site. Thus members of a large family of basic Helix-Loop-Helix E-box-binding proteins that includes MyoD and c-myc have the potential to bind this region. Complex III could be competed out by an oligonucleotide that contains a truncated E-box and the intact Mt-binding site (FXN E-boxDelta, F Figure 4, lane 5). Complex III thus probably represents the complex formed by a protein bound at the Mt-binding site. Thus, a number of proteins have the potential to bind to this region in vivo. Figure 4.Electrophoretic gel mobility shift analysis (EMSA) of proteins binding to FXN intron 1. EMSA was carried in the presence of molar excesses of E-boxcon, a canonical E-box sequence, FXN E-box which contains the FXN E-box together with the muscle-specific Mt-binding site, and FXN E-BoxDelta which contains the 3' end of the E-box together with the full Mt-binding site.
###end p 35
###begin p 36
###xml 74 77 74 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 180 183 180 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 209 212 209 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 274 277 274 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
Electrophoretic gel mobility shift analysis (EMSA) of proteins binding to FXN intron 1. EMSA was carried in the presence of molar excesses of E-boxcon, a canonical E-box sequence, FXN E-box which contains the FXN E-box together with the muscle-specific Mt-binding site, and FXN E-BoxDelta which contains the 3' end of the E-box together with the full Mt-binding site.
###end p 36
###begin title 37
###xml 51 54 51 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
Specific methylation of residue 13 does not affect FXN promoter activity
###end title 37
###begin p 38
###xml 62 65 62 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 160 167 160 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E. coli</italic>
###xml 276 278 276 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 290 293 290 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 671 679 671 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 714 720 714 720 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">per se</italic>
###xml 764 767 764 767 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 37 45 <span type="species:ncbi:9606">patients</span>
###xml 160 167 <span type="species:ncbi:562">E. coli</span>
The methylation of the E-box in FRDA patients could lead to a FXN deficit via a direct effect on the binding of one or more DNA-binding proteins. M.eco72I from E. coli RFL72 is a DNA methyltransferase that specifically methylates the CpG residue in the sequence 5'-CACGTG-3' (17). Thus the FXN E-box is a substrate for this enzyme and the site it methylates corresponds to residue 13. Since there are no other sites that can be methylated by this enzyme in the reporter construct, this methylase can be used to examine the effect of methylation of this residue specifically. Methylation had no effect on the activity of a reporter construct transfected into C2C12 cells (Figure 3C). Thus methylation of residue 13 per se is unlikely to be the primary cause of the FXN deficiency.
###end p 38
###begin title 39
Affected individuals have elevated levels of H3K9Me2
###end title 39
###begin p 40
###xml 360 368 360 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 388 391 388 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 443 451 443 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 589 591 589 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 727 730 727 730 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 760 762 760 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 897 900 897 900 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 923 925 923 925 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 928 937 928 937 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5.</label>
###xml 937 940 937 940 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 1026 1027 1026 1027 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 1043 1046 1043 1046 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 1305 1306 1305 1306 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1438 1439 1438 1439 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1451 1452 1451 1452 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 1454 1457 1454 1457 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 1573 1576 1573 1576 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GUS</italic>
###xml 937 1600 937 1600 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="41"><italic>FXN</italic> histone H3 K9 dimethylation and mRNA levels in unaffected and affected individuals. (<bold>A</bold>) The amount of <italic>FXN</italic> DNA immunoprecipitated by antibodies to histone H3-K9Me2 in each lymphoblastoid cell line was determined by real-time PCR as described in the Materials and Methods section. The data shown is an average of three independent ChIP experiments. In all instances <italic>P</italic> &lt; 0.002. When the data from all the patient samples was combined and compared to the combined data from the unaffected individuals <italic>P</italic> = 0.0001. (<bold>B</bold>) <italic>FXN</italic> RNA levels were determined in the indicated cell lines using real-time PCR and expressed relative to the amount of <italic>GUS</italic> mRNA in the same cells.</p>
###xml 937 1600 937 1600 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="41"><italic>FXN</italic> histone H3 K9 dimethylation and mRNA levels in unaffected and affected individuals. (<bold>A</bold>) The amount of <italic>FXN</italic> DNA immunoprecipitated by antibodies to histone H3-K9Me2 in each lymphoblastoid cell line was determined by real-time PCR as described in the Materials and Methods section. The data shown is an average of three independent ChIP experiments. In all instances <italic>P</italic> &lt; 0.002. When the data from all the patient samples was combined and compared to the combined data from the unaffected individuals <italic>P</italic> = 0.0001. (<bold>B</bold>) <italic>FXN</italic> RNA levels were determined in the indicated cell lines using real-time PCR and expressed relative to the amount of <italic>GUS</italic> mRNA in the same cells.</p></caption>
###xml 1600 1600 1600 1600 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkm271f5"/>
###xml 928 1600 928 1600 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F5" position="float"><label>Figure 5.</label><caption><p textid="41"><italic>FXN</italic> histone H3 K9 dimethylation and mRNA levels in unaffected and affected individuals. (<bold>A</bold>) The amount of <italic>FXN</italic> DNA immunoprecipitated by antibodies to histone H3-K9Me2 in each lymphoblastoid cell line was determined by real-time PCR as described in the Materials and Methods section. The data shown is an average of three independent ChIP experiments. In all instances <italic>P</italic> &lt; 0.002. When the data from all the patient samples was combined and compared to the combined data from the unaffected individuals <italic>P</italic> = 0.0001. (<bold>B</bold>) <italic>FXN</italic> RNA levels were determined in the indicated cell lines using real-time PCR and expressed relative to the amount of <italic>GUS</italic> mRNA in the same cells.</p></caption><graphic xlink:href="gkm271f5"/></fig>
###xml 245 253 <span type="species:ncbi:9606">patients</span>
###xml 580 587 <span type="species:ncbi:9606">patient</span>
###xml 1343 1350 <span type="species:ncbi:9606">patient</span>
Increased methylation of residue 13 may be a secondary consequence of a more compact chromatin organization which blocks factor binding. Since chromatin compaction is associated with elevated levels of H3K9Me2, we analyzed intron 1 in four FRDA patients for the presence of this histone modification. Elevated levels of H3K9Me2 were seen in these individuals (Figure 5A), all of whom had FXN mRNA levels 10-30% that of unaffected individuals (Figure 5B). While this manuscript was in preparation a similar observation was reported for another lymphoblastoid cell line from a FRDA patient (23). The increase in H3K9Me2 is consistent with the fact that treatment of FRDA lymphocytes with histone deacetylase inhibitors increases FXN transcription significantly (23) since H3K9 acetylation blocks K9 methylation. Our data thus support the idea that a chromatin-based mechanism is responsible for the FXN mRNA deficit in FRDA (23). Figure 5.FXN histone H3 K9 dimethylation and mRNA levels in unaffected and affected individuals. (A) The amount of FXN DNA immunoprecipitated by antibodies to histone H3-K9Me2 in each lymphoblastoid cell line was determined by real-time PCR as described in the Materials and Methods section. The data shown is an average of three independent ChIP experiments. In all instances P < 0.002. When the data from all the patient samples was combined and compared to the combined data from the unaffected individuals P = 0.0001. (B) FXN RNA levels were determined in the indicated cell lines using real-time PCR and expressed relative to the amount of GUS mRNA in the same cells.
###end p 40
###begin p 41
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 89 90 89 90 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 106 109 106 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 368 369 368 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 501 502 501 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 514 515 514 515 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 517 520 517 520 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 636 639 636 639 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GUS</italic>
###xml 406 413 <span type="species:ncbi:9606">patient</span>
FXN histone H3 K9 dimethylation and mRNA levels in unaffected and affected individuals. (A) The amount of FXN DNA immunoprecipitated by antibodies to histone H3-K9Me2 in each lymphoblastoid cell line was determined by real-time PCR as described in the Materials and Methods section. The data shown is an average of three independent ChIP experiments. In all instances P < 0.002. When the data from all the patient samples was combined and compared to the combined data from the unaffected individuals P = 0.0001. (B) FXN RNA levels were determined in the indicated cell lines using real-time PCR and expressed relative to the amount of GUS mRNA in the same cells.
###end p 41
###begin p 42
###xml 100 101 100 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 182 185 182 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 312 315 312 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 472 480 472 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 539 542 539 542 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 958 961 958 961 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 993 995 993 995 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 998 1007 998 1007 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 6.</label>
###xml 1007 1103 1007 1103 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="43">Model for chromatin organization in the region containing residue 13 in normal and FRDA alleles.</p>
###xml 1007 1103 1007 1103 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="43">Model for chromatin organization in the region containing residue 13 in normal and FRDA alleles.</p></caption>
###xml 1103 1103 1103 1103 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkm271f6"/>
###xml 998 1103 998 1103 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F6" position="float"><label>Figure 6.</label><caption><p textid="43">Model for chromatin organization in the region containing residue 13 in normal and FRDA alleles.</p></caption><graphic xlink:href="gkm271f6"/></fig>
The altered chromatin conformation may decrease transcription by impeding transcription elongation (9). Our data also suggests another way in which the chromatin modification at the FXN gene can lead to the mRNA deficit. In the absence of an expanded repeat tract, intron 1 binds proteins that positively affect FXN transcription. A secondary effect of this binding is that it creates natural 'methylation footprints' by protecting the binding sites from DNA methylation (Figure 6). The more compact chromatin formed on alleles with large FXN repeats blocks access of these proteins to the DNA as evidenced by disappearance of the 'methylation footprints'. Absence of binding of these transcription factors may lead to a reduction in transcription initiation. One implication of this model is that DNA methylation may be a secondary consequence of the histone modifications. This may explain why histone deacetylase inhibitors are so effective at increasing FXN gene expression in FRDA cells (23). Figure 6.Model for chromatin organization in the region containing residue 13 in normal and FRDA alleles.
###end p 42
###begin p 43
Model for chromatin organization in the region containing residue 13 in normal and FRDA alleles.
###end p 43
###begin p 44
###xml 19 22 19 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 270 272 270 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 360 362 360 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 412 414 412 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 459 461 459 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 40 47 <span type="species:ncbi:9606">patient</span>
How could the long FXN-repeat tracts in patient cells generate transcriptionally silent chromatin? One possibility is that this process involves small double-stranded RNAs (dsRNAs) that target the transcriptional silencing machinery to homologous regions of the genome (24). Potential sources of these dsRNAs are regions of transcripts that can form hairpins (25) or overlapping sense and antisense transcripts (26). Long GAA-repeat tracts form DNA hairpins (27). This raises the possibility that RNA containing these repeats may also do so. However, since a low level of modified chromatin exists at the frataxin locus even when the repeat number is too small to form stable hairpins, it is tempting to speculate that an antisense mechanism is involved at least when the repeat number is low.
###end p 44
###begin p 45
###xml 163 164 163 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
Repeat-mediated heterochromatin formation is seen in two other Repeat Expansion diseases: Fragile X syndrome and the congenital form of Myotonic Dystrophy type 1 (7). Thus repeat-mediated transcriptional silencing may provide a common thread linking these diseases where the repeat is transcribed but not translated.
###end p 45
###begin title 46
ACKNOWLEDGEMENTS
###end title 46
###begin p 47
The authors thank Ann Dean (NIDDK) for her thoughtful comments and advice. This work was supported by a grant from the Intramural Program of the NIDDK (NIH). Funding to pay the Open Access publication charges for this article was provided by the Intramural Program of the NIDDK (NIH).
###end p 47
###begin p 48
###xml 0 20 0 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Conflict of interest</italic>
Conflict of interest. None declared.
###end p 48
###begin title 49
REFERENCES
###end title 49
###begin article-title 50
The molecular basis of Friedreich ataxia
###end article-title 50
###begin article-title 51
###xml 102 110 <span type="species:ncbi:9606">patients</span>
Real time PCR quantification of frataxin mRNA in the peripheral blood leucocytes of Friedreich ataxia patients and carriers
###end article-title 51
###begin article-title 52
Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion
###end article-title 52
###begin article-title 53
The GAA*TTC triplet repeat expanded in Friedreich's ataxia impedes transcription elongation by T7 RNA polymerase in a length and supercoil dependent manner
###end article-title 53
###begin article-title 54
Alleviating transcript insufficiency caused by Friedreich's ataxia triplet repeats
###end article-title 54
###begin article-title 55
###xml 74 79 <span type="species:ncbi:10090">mouse</span>
The profile of repeat-associated histone lysine methylation states in the mouse epigenome
###end article-title 55
###begin article-title 56
DNA triplet repeats mediate heterochromatin-protein-1-sensitive variegated gene silencing
###end article-title 56
###begin article-title 57
Intragenic DNA methylation alters chromatin structure and elongation efficiency in mammalian cells
###end article-title 57
###begin article-title 58
Influence of the 5' intron in the control of acetylcholinesterase gene expression during myogenesis
###end article-title 58
###begin article-title 59
Direct regulation of myelin protein zero expression by the Egr2 transactivator
###end article-title 59
###begin article-title 60
Fgfr4 is required for effective muscle regeneration in vivo. Delineation of a MyoD-Tead2-Fgfr4 transcriptional pathway
###end article-title 60
###begin article-title 61
Intronic regulation of matrix metalloproteinase-2 revealed by in vivo transcriptional analysis in ischemia
###end article-title 61
###begin article-title 62
Multiple sequence alignment with hierarchical clustering
###end article-title 62
###begin article-title 63
Repbase update: a database and an electronic journal of repetitive elements
###end article-title 63
###begin article-title 64
The Friedreich ataxia GAA triplet repeat: premutation and normal alleles
###end article-title 64
###begin article-title 65
The eco72IC gene specifies a trans-acting factor which influences expression of both DNA methyltransferase and endonuclease from the Eco72I restriction-modification system
###end article-title 65
###begin article-title 66
Interaction of the transcription factors USF1, USF2, and alpha -Pal/Nrf-1 with the FMR1 promoter. Implications for Fragile X mental retardation syndrome
###end article-title 66
###begin article-title 67
###xml 56 61 <span type="species:ncbi:9606">human</span>
Ancient repeated DNA elements and the regulation of the human frataxin promoter
###end article-title 67
###begin article-title 68
Characterization of the primate-specific repetitive DNA element MER1
###end article-title 68
###begin article-title 69
###xml 40 45 <span type="species:ncbi:9606">human</span>
Expansion of GAA triplet repeats in the human genome: unique origin of the FRDA mutation at the center of an Alu
###end article-title 69
###begin article-title 70
Proposed roles for DNA methylation in Alu transcriptional repression and mutational inactivation
###end article-title 70
###begin article-title 71
Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia
###end article-title 71
###begin article-title 72
Regulation of heterochromatic silencing and histone H3 lysine-9 methylation by RNAi
###end article-title 72
###begin article-title 73
Homology-dependent gene silencing and host defense in plants
###end article-title 73
###begin article-title 74
Antisense transcription and heterochromatin at the DM1 CTG repeats are constrained by CTCF
###end article-title 74
###begin article-title 75
Hairpin formation in Friedreich's ataxia triplet repeat expansion
###end article-title 75

